tapebrief
CVS · Q4 2025

CVS · Q1 2026 Earnings

Cautious

CVS Health

Reported May 6, 2026

30-second summary

Q1 revenue grew 6.2% to $100.4B, adjusted EPS came in at $2.57, and GAAP EPS at $2.30, with HCB MBR of 84.6% — well below the FY guide of 90.5% ± 50bps and consistent with the steep Q1-to-Q4 seasonal swing management flagged last quarter. Management raised FY2026 adjusted EPS by $0.30 across the range to $7.30–$7.50, GAAP EPS by $0.30 to $6.24–$6.44, and operating cash flow to "at least $9.5B" from "at least $9.0B" — recovering half of the $1.0B cash flow cut taken in Q4. A new "at least $405.0B" revenue floor was disclosed for the first time. The raise is real but partial: the cash flow floor still sits $0.5B below the original December framing, and management explicitly held a "cautious view" on the back half citing "continued elevated cost trends and the potential for macro headwinds."

Headline numbers

EPS

Q1 FY2026

$2.57

Revenue

Q1 FY2026

$100.43B

+6.2% YoY

Free cash flow

Q1 FY2026

$3.40B

Operating margin

Q1 FY2026

4.7%

Key financials

Q1 FY2026
MetricQ1 FY2026YoYQ4 FY2025QoQ
Revenue$100.43B+6.2%$105.70B-5.0%
EPS$2.57—$1.09+135.8%
Operating margin4.7%—2.0%+266bps
Free cash flow$3.40B———

Guidance

UnitedHealth raised full-year 2026 GAAP EPS by $0.30 on both ends (+5% midpoint), Adjusted EPS by $0.30 (+4% midpoint), and operating cash flow by $0.5B, while introducing a $405B minimum revenue floor.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

MetricPeriodGuideYoY
Total RevenueFY 2026At least $405.0 billion—

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
GAAP Diluted EPS
FY 2026
$5.94 to $6.14$6.24 to $6.44+$0.30 at low end, +$0.30 at high endRaised
Adjusted EPS (non-GAAP)
FY 2026
$7.00 to $7.20$7.30 to $7.50+$0.30 at low end, +$0.30 at high endRaised
Cash Flow from Operations
FY 2026
At least $9.0 billionAt least $9.5 billion+$0.5 billionRaised

Segment KPIs

Q1 FY2026
SegmentQ1 FY2026YoY
Health Care Benefits$35.971B+3.3%
Health Services$48.237B+11.0%
Pharmacy & Consumer Wellness$31.989B+0.2%

Other KPIs

Q1 FY2026
SegmentQ1 FY2026
Medical Benefit Ratio (MBR)84.6%
Medical Membership26.0 million
Pharmacy Claims Processed464.7 million (30-day equivalent)
Prescriptions Filled451.2 million (30-day equivalent)
Days Claims Payable42.9 days
Operating Margin4.66%
Adjusted Operating Margin5.13%
Health Care Benefits Adjusted Operating Income Margin8.5%

Management tone

Q2 anchor: Aetna recovery → Q3 anchor: stabilization and rationalization → Q4 anchor: execution confidence → Q1 anchor: cautious raise.

The press release moved from Q4's "ambition to be the most trusted health care company in America" to Q1's "maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds." The shift from ambition language back to caution language — even as management raises every guided metric — is the most important tonal datapoint in the print. Management is choosing not to claim victory off a clean Q1.

Three quarters ago at Q3 2025, Caremark headwinds were framed as a structural multi-year recontracting problem; at Q4 PBM tone hardened with TrueCost characterized as "built for transparency, durability, and stable margins"; this quarter in Q&A the rebate guarantee performance is "tracking broadly in line with expectations" and the framing has moved to a model evolution — "from rebate guarantees to drug-level specific rebates and pricing guarantees." Per Michael Cherney's exchange, over 90% of client costs come from 10% of branded drugs, and TrueCost is positioned as the platform for this transition. The narrative arc is from problem-disclosure (Q3) → defensive confidence (Q4) → operational rollout (Q1). That is credibility-positive.

On HCB, the tone is conspicuously disciplined. The MBR printed at 84.6% — well below the FY guide of 90.5% ± 50bps — and yet management explicitly told Wells Fargo's Stephen Baxter in Q&A that "core outperformance from strong medical cost management" was not baked into the updated guide, with the FY MBR guide of 90.5% ± 50bps maintained. The Q4 brief flagged a watch item on whether Q1 MBR would print above the implied band; instead it printed comfortably below it, and management still refused to declare medical cost trends benign. This is the same disclosure discipline visible in Q3 2025 when management called the MA 2027 rate notice "disappointing" rather than spinning it.

The framing shift on AI is new. Per Andrew Mrock's question in Q&A, management is now positioning CVS as a "consumer-based healthcare technology company" — a meaningful escalation from prior quarters' more incremental references to digital and operational tooling. The three-bucket AI framework (cost structure, work-process improvement, member experience) and the Health 100 platform launch later in 2026 are the first concrete deliverables. This is worth tracking because the prior pattern at CVS has been to invest first and disclose value later.

The Tennessee PBM legislation introduced a new risk vector that didn't exist in prior quarters' tone. Per Lisa Gill's Q&A exchange, management is "considering legal action" against the Tennessee legislation (implementation mid-2028) and explicitly maintained the mid-teens EPS CAGR through 2028 despite the Tennessee headwind. The willingness to publicly flag legal action against a state regulator is a meaningful tonal escalation from prior quarters' more measured PBM regulatory commentary.

Q&A highlights

Justin Lake · Wolfe Research

Asked about 2027 Medicare Advantage rates and how they fit within the trajectory to achieve 3% MA margins by 2028.

Management emphasized strong partnership with CMS, acknowledged rates remain insufficient to offset medical cost trends, but affirmed confidence in hitting target margins by 2028 through disciplined strategy, improved geographic and product mix, and leading star scores carried into 2027.

Target MA margins of 3% by 2028 remains on track2027 rates acknowledged as not fully supporting elevated medical trendsYear-over-year improvement in Medicare Advantage business is 'really encouraging'Strong star scores to be carried into 2027

Michael Cherney · LeeWink Partners

Asked about Health Services timing dynamics on rebate guarantees, underlying business performance, and competitive/manufacturer dynamics affecting 2026 outlook.

Management noted Q1 reflected some timing benefit pulled forward from Q2, but adjusted for this, HSS modestly exceeded expectations. Rebate guarantee performance tracking in line with expectations. Management emphasized client focus on competition and transparency, transition from rebate guarantees to drug-level pricing guarantees, and TrueCost transparency platform.

Q1 benefited from timing pull-forward of expected Q2 valueRebate guarantee pressure tracking broadly in line with expectationsOver 90% of client costs from 10% of branded drugsTrueCost transparency platform launched over two years ago

Stephen Baxter · Wells Fargo

Asked about HCB guidance approach, whether net favorable PYD explains most of guidance range, whether conservative current-year cost trend assumptions remain, and whether core performance pockets are broad-based or selective.

Management attributed Q1 outperformance primarily to favorable PYD in government business and some core outperformance from strong medical cost management. Maintained conservative full-year outlook on medical cost trends due to early stage of year. Core outperformance not reflected in updated guidance. Noted strong performance across all lines of business including commercial, Medicare, and Medicaid.

Favorable prior year development primarily in government businessCore outperformance from strong medical cost management not baked into full-year guidanceRespectful and prudent view on medical cost trends maintained given early-year timingStrong performance across commercial, Medicare, and Medicaid lines

Andrew Mrock · Barclays

Asked about level and pace of AI investments in 2026, when AI shifts from net investment to net benefit, and timing for resuming share repurchases given improving leverage.

Management characterized company as moving from consumer-based healthcare to consumer-based healthcare technology company; described three-bucket approach to AI investment (cost structure, improving work processes, improving member experience). Regarding share repurchases, management stated focus remains on deleveraging; no buybacks contemplated in 2026 guidance but will evaluate opportunities throughout year as leverage improves.

Company positioning shift to healthcare technology companyAI investments in three areas: cost structure/efficiency, colleague enablement, member experience improvementsAI Academy launched for workforce upskillingHealth 100 platform powered by AI launching later in 2026

Lisa Gill · J.P. Morgan

Asked how company navigating federal and state-level PBM regulation (CAA, FTC settlement, state legislation like Tennessee), and whether meaningful changes in pharmacy business model separation will occur.

Management noted regulatory changes reinforce path already taken via TrueCost launch two years ago; transition to net-cost economics and transparency already underway. Federal changes provide clarity and durable reimbursement relief for independent pharmacies. Tennessee legislation viewed negatively as raising costs and threatening access; company evaluating legal action and other options with implementation in mid-2028. Emphasized clients seeking cost reduction and predictability amid regulatory uncertainty.

TrueCost transparency platform launched 2+ years ago in anticipation of regulatory shiftFederal changes (CAA, FTC settlement) reinforce existing direction toward net-cost economicsTennessee legislation implementation not until mid-2028Company considering legal action in response to Tennessee legislation

Answers to last quarter's watch list

FY2026 operating cash flow path against the "at least $9.0B" floor — guide raised to "at least $9.5B," recovering half of the $1.0B Q4 cut from the December Investor Day "at least $10.0B" framing. Q1 free cash flow was $3.4B. The floor format was maintained — management did not convert to a range.
Resolved positively
Q1 2026 MBR vs. the 850bps embedded seasonal swing — MBR printed at 84.6%, well below the FY guide midpoint of 90.5% and consistent with the steep Q1-to-Q4 seasonal swing management flagged at Q4. HCB adj. operating income margin of 8.5%. Per Q&A, the outperformance was attributed primarily to favorable PYD in government business plus some core medical cost management — and core outperformance was explicitly not flowed into FY guide.
Resolved positively
MA 2027 rate notice — final-rule downside or stars offsets — per Q&A, management acknowledged 2027 rates "not fully supporting elevated medical trends" but reaffirmed the 3% MA margin target by 2028, citing leading star scores carried into 2027 and disciplined geographic/product mix. No specific final-rule rate figure was quantified in the release.
Continue monitoring
Individual exchange risk adjustment — medical membership stepped down to 26.0M from 26.6M in Q4 (down 600k), consistent with individual exchange attrition. The press release and Q&A did not provide a specific individual exchange risk adjustment commentary.
Continue monitoring
Oak Street 2026 pre-tax loss disclosure — no explicit pre-tax loss figure, clinic-count sizing, or path-to-breakeven disclosure in the Q1 release. Q&A focused on HCB, HSS rebates, AI, and PBM regulation; Oak Street did not surface as a major Q&A topic.
Continue monitoring
Caremark 2026 selling-season net wins — the Q1 release did not refresh the $6B new client wins figure from Q3 2025. Q&A characterized the model as evolving toward drug-level pricing guarantees and TrueCost transparency, with over 90% of client costs concentrated in 10% of branded drugs. No fresh full-cycle Caremark win/loss disclosure.
Continue monitoring

What to watch into next quarter

Whether HCB MBR Q2 print remains comfortably within the 90.5% ± 50bps FY band — Q1 at 84.6% printed well below the band on Part D seasonality; Q2 is the cleanest read on whether the "core outperformance" management refused to flow into guide is durable or PYD-driven.

Operating cash flow trajectory toward closing the remaining $0.5B gap to the original December $10.0B framing — the Q1 raise to "at least $9.5B" recovered half the Q4 cut; watch whether Q2 prints support a further raise or whether the floor format persists, which would signal residual working-capital uncertainty.

Tennessee PBM litigation status and any other state-level legislative copycats — management is "considering legal action" with mid-2028 implementation; watch for legal-action filing and whether other states introduce similar PBM-separation legislation that could pressure the mid-teens EPS CAGR through 2028.

PCW revenue growth re-acceleration as Rite Aid integration laps — Q1 PCW at +0.2% YoY (vs. Q4 +12.4%) reflects the Rite Aid integration moving fully into base. Watch whether organic script growth and pharmacy share gains sustain margin contribution to FY guidance absent the M&A tailwind.

Caremark 2027 selling-season early indicators and TrueCost adoption — Q3 historically discloses next-year selling-season wins; watch whether Q2 prepared commentary frames the 2027 cycle similarly to the $6B 2026 figure disclosed at Q3 2025, and whether TrueCost is named as an adoption driver.

AI investment quantification and Health 100 platform launch detail — management positioned CVS as a "consumer-based healthcare technology company" and flagged Health 100 launch later in 2026; watch whether Q2 or Q3 provides specific investment dollar sizing or platform KPIs.

Sources

  1. CVS Health Q1 FY2026 press release (SEC 8-K, Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/64803/000006480326000051/cvs_ex99x1q1-26.htm
  2. CVS Health Q1 FY2026 earnings call Q&A excerpts (transcript partial).
  3. CVS Health Q4 FY2025 brief (Tapebrief, prior-quarter reference).
  4. CVS Health Q3 FY2025 brief (Tapebrief, prior-quarter reference).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.